Altered retinoblastoma protein expression in nonsmall cell lung cancer: Its synergistic effects with altered ras and p53 protein status on prognosis

Cancer

Volumn 79, Issue 7, 1997, Pages 1329-1337

  Dosaka Akita, Hirotoshi ^a   Hu, Shi Xue ^b   Fujino, Michihiro ^a   Harada, Masao ^a   Kinoshita, Ichiro ^a   Xu, Hong Ji ^b   Kuzumaki, Noboru ^a   Kawakami, Yoshikazu ^a   Benedict, William F ^b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

nonsmall cell lung cancer; p53 protein; prognosis; ras p21 protein; retinoblastoma protein

Indexed keywords

PROTEIN P21; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADENOCARCINOMA; AGE FACTORS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS); RETINOBLASTOMA PROTEIN; SEX FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030989021     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970401)79:7<1329::AID-CNCR9>3.0.CO;2-B     Document Type: Article

References (44)

1. Ginsberg RJ, Kris MG, Armstrong JG, Ihde DC, Pass HI, Glatstein EJ. Cancer of the lung. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 4th edition. Philadelphia: JB Lippincott, 1993: 673-758.
2. Minna JD. The molecular biology of lung cancer pathogenesis. Chest 1993;103:449S-56S.
3. Birrer MJ, Brown PH. Application of molecular genetics to the early diagnosis and screening of lung cancer. Cancer Res 1992;52:2658S-64S.
4. Gazdar AF. Molecular markers for the diagnosis and prognosis of lung cancer. Cancer 1992;69:1592-9.
5. Mulshine JL, Scott F. Molecular markers in early cancer detection. Chest 1995;107:280S-6S.
6. Mountain CF. New prognostic factors in lung cancer. Chest 1995;108:246-54.
7. Strauss GM, Kwiatkowski DJ, Harpole DH, Skarin AT, Sugarbaker DL. Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung. J Clin Oncol 1995;13:1265-79.
8. Harpole DH, Herndon JE, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 1995;55:51-6.
9. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteoblastoma. Nature 1986;323:643-6.
10. Fung YT, Murphree AL, T'Ang A, Qian J, Hinrichs SH, Benedict WF. Structural evidence for the authenticity of the human retinoblastoma gene. Science 1987;236:1657-61.
11. Lee W, Bookstein R, Hong F, Young L, Shew J, Lee EY. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 1987;235:1394-9.
12. Harbour JW, Lai S, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 1988;241:353-7.
13. Xu H, Hu S, Cagle PT, Moore GE, Benedict WF. Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. Cancer Res 1991;51:2735-9.
14. Reissmann PT, Koga H, Takahashi R, Figlin RA, Holmes EC, Piantadosi S, et al. Inactivation of the retinoblastoma susceptibility gene in non-small cell lung cancer. Oncogene 1993;8:1913-9.
15. Cance WG, Brennan MF, Dudas ME, Huang CM, Cordon-Cardo C. Altered expression of the retinoblastoma gene product in human sarcoma. N Engl J Med 1990;323:1457-62.
16. Cordon-Cardo C, Wartinger D, Petrylak D, Dalbagni G, Fair WR, Fuks Z, et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 1992;84:1251-6.
17. Logothetis CJ, Xu HJ, Ro JY, Hu SX, Sahin A, Ordonez N, et al. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 1992;84:1256-61.
18. Xu H, Quinlan DC, Davidson AG, Hu S, Summers CL, Li J, Benedict WF. Altered retinoblastoma protein expression and prognosis in early-stage non-small cell lung carcinoma. J Natl Cancer Inst 1994;86:695-9.
19. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989;246:491-4.
20. Chiba I, Takahashi T, Nau MM, D'Amico D, Curiel DT, Mitsudomi T, et al. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 1990;5:1603-10.
21. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
22. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992;52:4828-31.
23. Horio Y, Takahashi T, Kuroishi T, Hibi K, Suyama M, Niimi T, et al. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 1993;53:1-4.
24. Mitsudomi T, Oyama T, Kusano T, Osaki T, Nakanishi R, Shirakusa T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer. J Natl Cancer Inst 1993;85:2018-23.
25. Ebina M, Steinberg SM, Mulshine JL, Linnoila RI. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 1994;54:2496-503.
26. Fujino M, Dosaka-Akita H, Harada M, Hiroumi H, Kinoshita I, Akie K, et al. Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer. Cancer 1995; 76:2457-63.
27. Nishio M, Koshikawa T, Kuroishi T, Suyama M, Uchida K, Takagi Y, et al. Prognostic significance of abnormal p53 accumulation in primary, resected non-small cell lung cancer. J Clin Oncol 1996;14:497-502.
28. Rodenhuis S, Slebos RJC. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 1992;52:2665S-9S.
29. Harada M, Dosaka-Akita H, Miyamoto H, Kuzumaki N, Kawakami Y. Prognostic significance of the expression of ras oncogene product in non-small cell lung cancer. Cancer 1992;69:72-7.
30. World Health Organization. Histological typing of lung tumors. 2nd edition. Geneva: World Health Organization, 1981: 25-6.
31. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ. Lung. In: Manual for staging of cancer. 4th edition. Chicago: American Joint Committee on Cancer, 1992: 115-22.
32. Xu H, Hu S, Hashimoto T, Takahashi R, Benedict WF. The retinoblastoma susceptibility gene product: a characteristic pattern in normal cells and abnormal expression in malignant cells. Oncogene 1989;4:807-12.
33. Xu H, Hu S, Benedict WF. Lack of nuclear RB protein staining in G0/middle G1 cells: correlation to changes in total RB protein level. Oncogene 1991;6:1139-46.
34. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-81.
35. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 1965;52:203-23.
36. Harrell FE Jr. The PHGLM procedure. In: Hastings RP, editor. Supplementary library user's guide. Cary, NC: SAS Institute, 1986: 437-66.
37. Xu H, Cagle PT, Hu S, Li J, Benedict WF. Altered RB and p53 protein status in non-small cell carcinoma of the lung: potential synergistic effects on prognosis. Clin Cancer Res 1996;2:1169-76.
38. Miyamoto H, Harada M, Isobe H, Dosaka-Akita H, Haneda H, Yamaguchi E, et al. Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer. Cancer Res 1991;51:6346-50.
39. Kern JA, Slebos RJC, Top B, Rodenhuis S, Lager D, Robinson R, et al. c-erb B-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 1994;93:516-20.
40. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994;368:753-6.
41. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
42. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumor suppressor p16. Nature 1995;375:503-6.
43. INK4 expression in primary lung cancers. Cancer Res 1995;55:505-9.
44. Nakagawa K, Conrad NK, Williams JP, Johnson BE, Kelley MJ. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. Oncogene 1995;11:1843-51.